<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40986">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572817</url>
  </required_header>
  <id_info>
    <org_study_id>IRC-005</org_study_id>
    <nct_id>NCT02572817</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A</brief_title>
  <official_title>A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of anti-influenza immune plasma, as an
      addition to standard of care antivirals, in participants hospitalized with severe influenza
      A infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite antivirals and vaccines, influenza is responsible for thousands of hospitalizations
      and deaths each year worldwide. Because of this, additional treatments for influenza are
      needed. One potential treatment may be the use of high-titer anti-influenza immune plasma.
      The purpose of this study is to evaluate the efficacy and safety of treatment with
      high-titer versus low-titer anti-influenza immune plasma, in addition to standard care, in
      participants hospitalized with severe influenza A infection.

      This study will enroll people aged 2 weeks or older who are hospitalized with severe
      influenza A infection. Participants will be randomly assigned to receive either high-titer
      anti-influenza plasma or low-titer (control) anti-influenza plasma on Day 0. In addition,
      all participants will receive standard care antivirals. Participants will be assessed on Day
      0 (baseline) and on Days 1, 2, 3, 7, 14, and 28. For participants who are not hospitalized
      on Days 2, 14, and 28, researchers may contact participants by telephone. Study procedures
      will include clinical assessments, blood collection, and oropharyngeal swabs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects clinical status at Day 7 (6-point ordinal scale)</measure>
    <time_frame>Measured at Day 7</time_frame>
    <description>death;
in ICU;
non-ICU hospitalization, requiring supplemental oxygen;
non-ICU hospitalization, not requiring supplemental oxygen;
not hospitalized, but unable to resume normal activities; or
not hospitalized with full resumption of normal activities</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Influenza A Virus Infection</condition>
  <arm_group>
    <arm_group_label>High-titer anti-influenza plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-titer (control) anti-influenza plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-titer anti-influenza plasma</intervention_name>
    <description>Human plasma (FFP or FP24, 250-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80</description>
    <arm_group_label>High-titer anti-influenza plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Low-titer (control) anti-influenza plasma</intervention_name>
    <description>Human plasma (FFP or FP24, 250-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less</description>
    <arm_group_label>Low-titer (control) anti-influenza plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Enrollment (Screening):

          -  Subjects must be aged 2 weeks or older.

          -  Hospitalization due to signs and symptoms of influenza (decision for hospitalization
             will be up to the individual treating clinician).

          -  Study plasma available on-site or available within 24 hours after randomization.

          -  Not previously screened nor randomized in this study.

        Inclusion Criteria for Randomization:

          -  Locally determined positive test for influenza A (by polymerase chain reaction [PCR],
             other nucleic acid testing, or by rapid Ag) from a specimen obtained less than or
             equal to 48 hours prior to randomization.

          -  Onset of illness less than or equal to 6 days before randomization, defined as when
             the subject first experienced at least one respiratory symptom or fever.

          -  Hospitalized due to influenza, with anticipated hospitalization for more than 24
             hours after randomization. Criteria for hospitalization will be up to the individual
             treating clinician.

          -  Willingness to have blood and respiratory samples obtained and stored.

          -  Willingness to return for all required study visits and participate in study follow
             up.

          -  National Early Warning (NEW) score greater than or equal to 3 within 12 hours prior
             to randomization (or PEW [pediatric early warning] score greater than or equal to 3
             within 12 hours prior to randomization).

          -  ABO-compatible plasma available on-site or available within 24 hours after
             randomization.

        Exclusion Criteria for Randomization:

          -  Strong clinical evidence in the judgment of the site investigator that the etiology
             of illness is primarily bacterial super-infection in origin. Co-infection would be
             allowed, as there may be benefit to resolving influenza illness faster.
             Super-infection, where influenza illness occurred and is resolving, and new bacterial
             illness causing deterioration should be excluded.

          -  Prior treatment with any anti-influenza investigational drug, intravenous immune
             globulin (IVIG), or plasma therapy within 30 days prior to screening. Other
             investigational drug therapies (non-influenza) are allowed.

          -  History of allergic reaction to blood or plasma products (as judged by the site
             investigator).

          -  A pre-existing condition or use of a medication that, in the opinion of the site
             investigator, may place the individual at a substantially increased risk of
             thrombosis (e.g., cryoglobulinemia, severe refractory hypertriglyceridemia, or
             clinically significant monoclonal gammopathy). Prior IVIG use alone would not meet
             exclusion criteria, but the investigator should consider the potential for a
             hyper-coagulable state.

          -  Subjects who, in the judgment of the site investigator, will be unlikely to comply
             with the requirements of this protocol, including being uncontactable following
             discharge from hospital.

          -  Medical conditions for which receipt of 500-600 mL of intravenous fluid may be
             dangerous to the subject (e.g., decompensated congestive heart failure).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Beigel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, National Institutes of Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DCR Flu Operations</last_name>
    <email>DCRFluOperations@s-3.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lutrick</last_name>
      <phone>520-626-8000</phone>
      <email>klutrick@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Romero, MD</last_name>
      <phone>501-364-1416</phone>
      <email>romerojose@uams.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Pediatrics Infectious Diseases</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Deville, MD</last_name>
      <phone>310-825-9660</phone>
      <email>JDeville@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center San Diego (NMCSD)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Danko, MD</last_name>
      <phone>301-295-8279</phone>
      <email>janine.r.danko.mil@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suchitra Rao, MBBS</last_name>
      <phone>720-777-2823</phone>
      <email>Suchitra.rao@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Albrecht, BSN, CCRA</last_name>
      <phone>303-724-7618</phone>
      <email>douglas.albrecht@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Cullen</last_name>
      <phone>203-384-4849</phone>
      <email>Tina.Cullen@bpthosp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meenakshi Puthucode Balakrishnan</last_name>
      <phone>352-265-5911</phone>
      <email>meenakshipb@ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Al-Saden, RN, CCRC</last_name>
      <phone>312-694-0232</phone>
      <email>palsaden@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lin, MD, MPH</last_name>
      <phone>312-942-5865</phone>
      <email>Michael_Lin@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William P. Tillis, MD</last_name>
      <phone>309-672-5682</phone>
      <email>William.p.tillis@osfhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Winokur, MD</last_name>
      <phone>319-384-1735</phone>
      <email>patricia-winokur@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lewis Rubinson, MD, PhD</last_name>
      <phone>410-328-3495</phone>
      <email>LRubinson@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darin Ostrander, PhD</last_name>
      <phone>443-742-0256</phone>
      <email>dostran1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center (WRNMMC)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Danko, MD</last_name>
      <phone>301-295-8279</phone>
      <email>janine.r.danko.mil@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Beigel, MD</last_name>
      <phone>301-451-9881</phone>
      <email>jbeigel@niaid.nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>021141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Anne Holland, R.N., B.S.N</last_name>
      <phone>617-726-3498</phone>
      <email>caholland@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Randolph, MD</last_name>
      <phone>617-355-7327</phone>
      <email>adrienne.randolph@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Longtine, RN, BS, CCRC</last_name>
      <phone>508-856-6970</phone>
      <email>Karen.Longtine@umassmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Nelson, BSN</last_name>
      <phone>734-232-4285</phone>
      <email>flygrrl@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital - Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Clark, MD</last_name>
      <phone>248-898-3080</phone>
      <email>Carol.Clark@Beaumont.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Campus Saint Mary's</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suanne Weist, RN</last_name>
      <phone>507-255-6804</phone>
      <email>Weist.suanne@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital at Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lin, MD</last_name>
      <phone>314-286-1746</phone>
      <email>lin_j@kids.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Morrow, MD</last_name>
      <phone>402-449-5680</phone>
      <email>lmorrow@creighton.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University/Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Deygoo</last_name>
      <phone>212-263-5680</phone>
      <email>sandra.deygoo@med.nyu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Quackenbush, MD</last_name>
      <phone>919-843-1825</phone>
      <email>eugenia_quackenbush@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Kearney Bryan</last_name>
      <phone>704-355-0244</phone>
      <email>Jessica.kearney-bryan@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Wrenn</last_name>
      <phone>919-681-2554</phone>
      <email>samantha.wrenn@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Stalets, MD</last_name>
      <phone>513-636-4259</phone>
      <email>Erika.stalets@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Robertson, LPN</last_name>
      <phone>405-271-6173</phone>
      <email>Jennifer-robertson@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Quinn, RN, BSN</last_name>
      <phone>215-349-8092</phone>
      <email>joseph.quinn@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Lynn Pakstis</last_name>
      <phone>412-648-6553</phone>
      <email>dlp5@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tianna Petersen</last_name>
      <phone>214-590-0611</phone>
      <email>tianna.petersen@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>JBSA Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Danko, MD</last_name>
      <phone>301-295-8279</phone>
      <email>janine.r.danko.mil@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Peng</last_name>
      <phone>802-656-3506</phone>
      <email>alice.peng@uvmhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Marshall, RN</last_name>
      <phone>434-924-2804</phone>
      <email>mhm2m@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Danko, MD</last_name>
      <phone>301-295-8279</phone>
      <email>janine.r.danko.mil@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McGuire, MD</last_name>
      <phone>206-987-2170</phone>
      <email>john.mcguire@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center (MAMC)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Danko, MD</last_name>
      <phone>301-295-8279</phone>
      <email>janine.r.danko.mil@mail.mil</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>October 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Influenza Immune Plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
